Risk factors for severe and critically ill COVID‐19 patients: A review
Tóm tắt
The pandemic of coronavirus disease 2019 (COVID‐19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has caused an unprecedented global social and economic impact, and high numbers of deaths. Many risk factors have been identified in the progression of COVID‐19 into a severe and critical stage, including old age, male gender, underlying comorbidities such as hypertension, diabetes, obesity, chronic lung diseases, heart, liver and kidney diseases, tumors, clinically apparent immunodeficiencies, local immunodeficiencies, such as early type I interferon secretion capacity, and pregnancy. Possible complications include acute kidney injury, coagulation disorders, thoromboembolism. The development of lymphopenia and eosinopenia are laboratory indicators of COVID‐19. Laboratory parameters to monitor disease progression include lactate dehydrogenase, procalcitonin, high‐sensitivity C‐reactive protein, proinflammatory cytokines such as interleukin (IL)‐6, IL‐1β, Krebs von den Lungen‐6 (KL‐6), and ferritin. The development of a cytokine storm and extensive chest computed tomography imaging patterns are indicators of a severe disease. In addition, socioeconomic status, diet, lifestyle, geographical differences, ethnicity, exposed viral load, day of initiation of treatment, and quality of health care have been reported to influence individual outcomes. In this review, we highlight the scientific evidence on the risk factors of severity of COVID‐19.
Từ khóa
Tài liệu tham khảo
World Health Organizatio (WHO).Coronavirus disease (COVID2019) situation reports.https://www.who.int/emergencies/diseases/novel‐coronavirus‐2019/situation‐reports. Accessed Oct 22 2020
Attaway AA, 2020, SARS‐CoV‐2 infection in the COPD population is associated with increased healthcare utilization: An analysis of Cleveland clinic's COVID‐19 registry, EClinicalMedicine., 100515
Kuo CL, 2020, COVID‐19 severity is predicted by earlier evidence of accelerated aging, medRxiv.
Zakeri R, 2020, A case‐control and cohort study to determine the relationship between ethnic background and severe COVID‐19, EClinicalMedicine., 100574
Centers for Disease Control and Prevention.People who are at higher risk for severe illness.2020.https://www.cdc.gov/coronavirus/2019‐ncov/need‐extra‐precautions/index.html. Accessed 11 Sept 2020
Brar G, 2020, COVID‐19 severity and outcomes in patients with cancer: a matched cohort study, J Clin Oncol., 2001580
Hagman K, 2020, SARS‐CoV‐2 RNA in serum as predictor of severe outcome in COVID‐19: a retrospective cohort study, Clin Infect Dis.
Frediansyah A, 2020, Remdesivir and its antiviral activity against COVID‐19: A systematic review, Clin Epidemiol Glob Health.
Karimi M, 2020, Prevalence and clinical features of COVID‐19 in Iranian patients with congenital coagulation disorders, Blood Transfus., 18, 413
Chen C, 2020, Analysis of myocardial injury in patients with COVID‐19 and association between concomitant cardiovascular diseases and severity of COVID‐19, Zhonghua Xin Xue Guan Bing Za Zhi., 48, 567
Dahan S, 2020, Ferritin as a marker of severity in COVID‐19 patients: a fatal correlation, Isr Med Assoc J., 8, 429
Ruscitti P, 2020, Ferritin and severe COVID‐19, from clinical observations to pathogenic implications and therapeutic perspectives, The Israel Medical Association J., 8, 450
WHO.Smoking and COVID‐19. WHO scientific brief 2020.
Gulsen A, 2020, The effect of smoking on COVID‐19 symptom severity: Systematic review and meta‐analysis, MedRxiv., 2020, 15.20102699